Highest development stage: Preclinical

Development status: Inactive

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Good activty against gram negative bacteria with the exception of Pseudomonas.

Reason dropped: Discontinued in 1994 due to…

Additional information: Chin, N. X., and H. C. Neu. "Tigemonam, an oral monobactam." Antimicrobial agents and chemotherapy 32.1 (1988): 84-91.